We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hematological Biomarkers Predict Prognosis in Hepatocellular Carcinoma

By LabMedica International staff writers
Posted on 12 Oct 2020
Print article
Image: Photomicrograph of histopathology of hepatocellular carcinoma, the most common form of primary liver cancer, showing end-stage cirrhosis - blue collagen (fibrosis) Mallory bodies; loss of normal liver architecture; and nuclear atypia. (Photo courtesy of Nephron).
Image: Photomicrograph of histopathology of hepatocellular carcinoma, the most common form of primary liver cancer, showing end-stage cirrhosis - blue collagen (fibrosis) Mallory bodies; loss of normal liver architecture; and nuclear atypia. (Photo courtesy of Nephron).
Hepatocellular carcinoma (HCC) is an inflammation-related cancer, where non-resolving inflammation contributes to its development and progression. Peripheral inflammatory cells have been shown to be associated with the prognosis of various types of cancer.

Immune cells conduct their functions in the tumor microenvironment, and in the peripheral blood to promote metastasis The quantification of peripheral blood inflammatory cells such as neutrophils, lymphocytes, monocytes, and platelets, as well as their ratios, have been identified and validated as novel biomarkers with prognostic significance in several cancers.

A team of hepatologists at the Pusan National University School of Medicine (Yangsan, Republic of Korea) and their associate retrospectively analyzed 1,681 patients with HCC who were newly diagnosed between November 2008 and March 2018. Included in the study were 1,335 (79.4%) males and 346 (20.6%) females. The patients ranged in age from 27 to 88 years, and the median age was 60 years. Hepatitis B, hepatitis C, and alcoholic liver disease were diagnosed in 1,039 (61.8%), 279 (16.6%), and 184 (11.0%) patients, respectively. The frequency of patients with underlying liver cirrhosis was 85.1%.

All pretreatment routine blood cell examinations that were performed within two weeks before treatment were used for the analysis. Overall survival (OS) was calculated from the date of HCC diagnosis to the date of death or last follow-up. OS was compared for between patients with high and low neutrophils, lymphocytes, and monocytes (dichotomized by median values).

The scientist used univariate and multivariate analyses, and found that individual neutrophil, lymphocyte and monocyte cell counts were independent indicators of poor OS. High neutrophil (≥3100 × 106/L) and, monocyte (≥470 × 106/L) counts and low lymphocyte counts (< 1640 × 106/L) significantly associated with reduced OS. Neutrophil and, monocyte cell counts rose and lymphocyte counts decreased in association with advancing the Barcelona Clinic Liver Cancer stage.

The team also analyzed the combination score and found that higher neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lower lymphocyte to monocyte ratio (LMR) had worse OS. Patients with high neutrophils and monocytes were more likely to have larger tumor size. The presence of vascular invasion was associated with high neutrophil and, monocyte counts and with low lymphocyte counts. High neutrophils and monocyte counts were associated with extrahepatic metastasis.

The authors concluded that pretreatment peripheral neutrophils, lymphocytes, and monocytes are independently associated with outcomes of patients with HCC. These cells provide a noninvasive, low-cost, easy, and reproducible biomarker that can be used in routine clinical practice to predict the prognosis of patients with HCC. The study was published on September 29, 2020 in the journal BMC Cancer.

Related Links:
Pusan National University School of Medicine

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.